This is a Phase 2 open label study of an orally administered lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat, in participants with polycythemia vera. The primary hypothesis is that bomedemstat is a
Trial Drug: Bomedemstat
This is a Phase 2 open label study of an orally administered LSD1 inhibitor, bomedemstat (IMG-7289), in patients with polycythemia vera.
This study investigates the following:
- The safety and tolerability of bomedemstat
- The pharmacodynamic effect of bomedemstat